UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
Urogen Pharma (URGN) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
Urogen Pharma (URGN) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Urogen Pharma (URGN) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $40.00 price target on the stock.
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer